<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357331</url>
  </required_header>
  <id_info>
    <org_study_id>0604008486</org_study_id>
    <nct_id>NCT00357331</nct_id>
  </id_info>
  <brief_title>The Effects of Potassium Citrate on Bone Metabolism</brief_title>
  <official_title>A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss
      over time. Evidence from a few small short-term studies suggests that basic compounds, namely
      potassium citrate and potassium bicarbonate may reduce bone loss and improve bone density.

      The purpose of this study is to evaluate the effects of potassium citrate on bone metabolism.
      We hypothesize that administration of potassium citrate to postmenopausal women with
      osteopenia will reduce bone resorption and improve bone mineral density.

      Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of
      fracture will be randomized to either daily potassium citrate or placebo for one year.
      Primary outcomes will be markers of bone turnover, which will be measured over 12 months.
      Secondary outcomes will be bone mineral density, compliance, and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were recruited from a single academic center. Subjects underwent screening at
      the Clinical Translational Science Center (CTSC) at Weill Cornell Medical College (WCMC).
      Study visits occurred at the CTSC where investigators administered and monitored
      questionnaires, compliance, adverse events, and endpoint measurements. Subjects were assigned
      an anonymous study number at the beginning of the trial, which was used to track the
      participant's data throughout the study. The protocol was approved by the Institutional
      Review Board (IRB) and the procedures followed were in accordance with the ethical standards
      of the IRB and the CTSC. All patients provided informed consent.

      Treatment Groups Participants were assigned to either the treatment or placebo group using a
      randomization schema generated by the statistician. The randomization method was blocked
      randomization with a blocking factor of 4. The blocked randomization was not stratified by
      any other factors. The study was conducted in a double blind manner. The study medication,
      K-citrate, or placebo, was dispensed through the New York Presbyterian Hospital (NYPH)
      pharmacy. Bottles in the pharmacy were sequentially numbered and the number was linked to the
      blocked randomization scheme. Only the statistician and the pharmacist knew the meaning of
      the numbered codes and only the statistician knew the blocking assignment. Blocked
      randomization with balanced randomization of each block and blocks of the same size was
      performed by the RANDOM procedure within the WinPepi Version 11.1.

      Investigators who administered questionnaires and assessed compliance, adverse effects or
      endpoint information were blind to group assignment. Only study investigators were able to
      enroll participants in the study and assign them to treatment arms. Those assigned to the
      treatment group received the study drug (40 mEq daily K Citrate: two 10 mEq tablets twice
      daily); those assigned to the control group received inert tablets of the same quantity. All
      participants received daily supplementation with Citracal (630 mg calcium citrate and 400 IU
      vitamin D3 per two caplets). All supplements and medications were provided by Mission
      Pharmacal/Bayer Pharmaceuticals in Boerne, Texas. Subjects discontinued their prior
      supplements at the time of entry to the study and were advised to adhere to the standardized
      supplementation regimen outlined by the protocol.

      Measurements and Outcomes Subjects were evaluated at baseline, 1, 3, 6, and 12 months. The
      following outcomes were measured: change in bone turnover markers including u-NTX, BSAP, OC
      and P1NP; changes in 24 hour urinary concentrations of citrate, sulfate, and calcium; and
      changes in BMD measured from baseline to 12 months. Adverse events and compliance were
      measured at each visit over the study duration. Adverse events pertained to medication side
      effects, including, but not limited to, gastrointestinal complaints, nausea, diarrhea, and
      stomach pain, as well as the development of hyperkalemia or metabolic acidosis. If any of the
      following occurred, potassium exceeded 5.2 mmol/L; bicarbonate level exceeded 32 mmol/L;
      creatinine increased by more than 30% or rose above 2.0 ng/dL; or GFR was &lt; 60, study
      medications were stopped until the parameter normalized, at which point the medication was
      resumed at half dose: Compliance was assessed by remaining pill count; good compliance was
      defined at ≤ 20% of pills remaining, or ≤ 18 pills remaining for each 3-month dose
      allocation.

      Baseline measurements included dietary assessment (block food frequency questionnaire) and
      blood pressure. Laboratory evaluation was performed at the General Core Laboratory at WCMC
      and included a basic metabolic panel, calcium, albumin and thyroid stimulating hormone (TSH).
      25-OH and 1,25(OH)2 Vitamin D were measured by radioimmunoassay (Immunodiagnostic Systems,
      Scottsdale, Arizona). The interassay coefficient of variation (CV) was &lt;8.2% and &lt;13%,
      respectively. Intact parathyroid hormone (i-PTH) was measured by immunoradiometric assay
      (Scantibodies Laboratories, Santee, California; CV &lt;6.4%). Markers of bone turnover included
      osteocalcin (OC: quantitative immunoradiometric assay, DiaSorin, Stillwater, Minnesota; CV
      &lt;9.5%) , bone specific alkaline phosphatase (BSAP: solid phase monoclonal antibody
      immunoenzymetric assay, Immunodiagnostics Systems, Scottsdale, Arizona; CV&lt;6.4%), procollagen
      type 1 amino-terminal propeptide (P1NP: quantitative radioimmunoassay, Orion Diagnostica,
      Espoo, Finland; CV&lt;9.8%), urinary N-telopeptide (U-NTX: quantitative enzyme-linked
      immunosorbent assay kit, Wampole Laboratories INC Princeton, New Jersey; CV&lt;5.0%). All
      specimens were collected as fasting morning samples. The urinary-NTX was a second morning
      void. The specimens were frozen and batch analyzed. 24 hour urinary collections for calcium,
      creatinine, sulfate, citrate and sodium were analyzed at Quest Diagnostics. BMD was performed
      at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA)
      Hologic; Bedford, Massachusetts. The least significant change (LSC) for the DXA was 0.025 at
      the lumbar spine, 0.025 at the femoral neck and 0.015 at the radius. Two technologists, both
      certified by the International Society for Clinical Densitometry, performed all DXA testing
      on the participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary-N-telopeptide</measure>
    <time_frame>Baseline,1,3,6,12 months</time_frame>
    <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P1NP (Amino-terminal Propeptide of Type I Procollagen)</measure>
    <time_frame>Baseline,1,3,6,12 months</time_frame>
    <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</measure>
    <time_frame>1 year</time_frame>
    <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Bone Diseases, Metabolic</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Potassium Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium Citrate 20 meq twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium citrate</intervention_name>
    <description>20 meq by mouth in capsule form twice daily</description>
    <arm_group_label>Potassium Citrate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>uro cit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women, more than 2 years post menopause

          -  Osteopenia, defined as a T score at the lumbar spine or total hip between -1.0 and
             -2.5

          -  No history of prior fragility fracture

        Exclusion criteria:

          -  Renal insufficiency

          -  Use of potassium sparing diuretics

          -  Use of potassium supplements

          -  Hyperkalemia

          -  Secondary causes of osteoporosis or metabolic bone disease

          -  Delayed gastric emptying

          -  esophageal compression, intestinal obstruction or stricture

          -  use of anticholinergic medication

          -  active urinary tract infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naina Sinha Gregory, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gregory NS, Kumar R, Stein EM, Alexander E, Christos P, Bockman RS, Rodman JS. POTASSIUM CITRATE DECREASES BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL. Endocr Pract. 2015 Dec;21(12):1380-6. doi: 10.4158/EP15738.OR. Epub 2015 Sep 24.</citation>
    <PMID>26401577</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmenopausal osteopenia</keyword>
  <keyword>treatment</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Citrate</title>
          <description>Potassium Citrate 20 meq twice daily
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo 20 meq by mouth in capsule form twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Potassium Citrate</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="7.1"/>
                    <measurement group_id="B2" value="65.1" spread="5.9"/>
                    <measurement group_id="B3" value="65.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>New York City &amp; Surrounding Environs</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="2.5"/>
                    <measurement group_id="B2" value="24" spread="3.3"/>
                    <measurement group_id="B3" value="23" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTH</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="25"/>
                    <measurement group_id="B2" value="56.9" spread="33.4"/>
                    <measurement group_id="B3" value="57.2" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-OH Vitamin D</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="12.7"/>
                    <measurement group_id="B2" value="31.3" spread="13.3"/>
                    <measurement group_id="B3" value="33.3" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary-N-telopeptide</title>
        <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
        <time_frame>Baseline,1,3,6,12 months</time_frame>
        <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary-N-telopeptide</title>
          <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
          <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
          <units>nml BCE/nmol creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="19.6"/>
                    <measurement group_id="O2" value="51.6" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="22.5"/>
                    <measurement group_id="O2" value="47" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="21.2"/>
                    <measurement group_id="O2" value="40.5" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="11.6"/>
                    <measurement group_id="O2" value="41.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="13.9"/>
                    <measurement group_id="O2" value="41.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</title>
        <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</title>
          <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>P1NP (Amino-terminal Propeptide of Type I Procollagen)</title>
        <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
        <time_frame>Baseline,1,3,6,12 months</time_frame>
        <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>P1NP (Amino-terminal Propeptide of Type I Procollagen)</title>
          <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
          <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
          <units>micrograms/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="20.1"/>
                    <measurement group_id="O2" value="55.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="19.2"/>
                    <measurement group_id="O2" value="48.1" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="18.3"/>
                    <measurement group_id="O2" value="43.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="15.0"/>
                    <measurement group_id="O2" value="43.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="16.5"/>
                    <measurement group_id="O2" value="42.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Potassium Citrate</title>
          <description>Potassium Citrate 20 meq twice daily
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Traumatic Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possible dual effect of calcium citrate, which mitigated the net effect of the alkalinizing treatment. The dose of K-citrate may not be sufficient to produce a change in BMD. Duration of treatment may have been too short to see changes in BMD.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Assistant Professor of Medicine</name_or_title>
      <organization>Weill Medical College</organization>
      <phone>212-746-1670</phone>
      <email>sinhana@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

